Analyst initiations 9-6-07: MSFT, CRM, TLEO and MFE
Posted Sep 6th 2007 11:13AM by Eric Buscemi
Filed under: Analyst reports, Microsoft (MSFT), Analyst initiations, salesforce.com inc (CRM), Zoltek Co (ZOLT)
MOST NOTEWORTHY: European pharmaceuticals, Microsoft, Salesforce.com, Taleo and McAfee were today's noteworthy initiations:
- UBS resumed coverage of Novartis AG (NYSE: NVS) with a Buy rating and AstraZeneca (NYSE: AZN), Roche Holding (OTC: RHHBY), Sanofi-Aventis (NYSE: SNY) and GlaxoSmithKline (NYSE: GSK) with Neutral ratings.
- Deutsche Bank believes new product leverage can bring upside to consensus operating margin expectations at Microsoft Corporation (NASDAQ: MSFT) and they view shares as attractively valued given its growth profile. The firm started shares with a Buy rating and $33 target.
- Keybanc initiated shares of Salesforce.com (NYSE: CRM) with a Hold rating and sees slowing growth rates for revenue and net subscriber additions throughout the remainder of FY08 and beyond and thinks investor expectations are too high.
- Keybanc also started shares of Taleo Corporation (NASDAQ: TLEO) with a Buy rating and $27 target, as it is well-positioned to gain market share in the Human Capital Management space.
- Thomas Weisel believes McAfee Inc (NYSE: MFE) will benefit from PC market growth, enhanced awareness of the company's brand, and its renewed focus on product development for the midmarket corporate segment, and started shares with a Market Weight rating and $37 target.
OTHER INITIATIONS:
Tags: analyst, astrazeneca, azn, bfc financial, BfcFinancial, bff, capital product partners, CapitalProductPartners, cplp, crm, firm, glaxosmithkline, gsk, initiation, lulu, lululemon, mcafee, mfe, microsoft, msft, novartis, nvs, rhhby, roche holding, RocheHolding, salesforce.com, sanofi-aventis, sny, taleo, tleo, zolt, zoltek